Patent Assignment
Reel/Frame 042389/0505
Change of Name
Recorded: 2017-05-03
Pages: 9
Assignor
DENDREON PHARMACEUTICALS, INC.
Executed: 2017-04-12
Assignee
DENDREON PHARMACEUTICALS LLC
400 SOMERSET CORPORATE BLVD., BRIDGEWATER, NEW JERSEY, 08807
Covered Properties
(51)
Novel Neutrophil Inhibitors
Patent:
6,756,211 →
Application:
08/060,433 →
Novel Neutrophil Inhibitors
Patent:
6,962,795 →
Application:
08/151,064 →
Novel Neutrophil Inhibitors
Patent:
6,818,616 →
Application:
08/450,482 →
Growth Arrest Gene Compositions and Methods
Patent:
5,998,599 →
Application:
08/883,070 →
Substituted 3-Amino-2-Hydroxyphenylacetamide Derivatives as Enzyme Inhibitors
Patent:
6,011,047 →
Application:
08/980,114 →
Process for Making Silanized Colloidal Silica
Patent:
6,015,843 →
Application:
09/006,775 →
Prostate Tumor Polynucleotide Compositions and Methods of Detection Thereof
Patent:
6,194,152 →
Application:
09/112,096 →
Resin Derivatization Method and Uses Thereof
Patent:
6,787,612 →
Application:
09/122,576 →
Compositions and Methods for Enhancement of Major Histocompatibility Complex Class I Restricted Antigen Presentation
Patent:
7,148,324 →
Application:
09/461,684 →
Inhibitors of Serine Protease Activity of Matriptase or MTSP1
Patent:
6,797,504 →
Application:
09/657,986 →
Plasminogen Activator Inhibitor Antagonists
Patent:
6,677,473 →
Application:
09/716,036 →
Nucleic Acids Encoding Endotheliases, Endotheliases and Uses Thereof
Patent:
7,276,364 →
Application:
09/717,473 →
Nucleic Acid Molecules Encoding Transmembrane Serine Proteases, the Encoded Proteins and Methods Based Thereon
Compositions and Methods for Dendritic Cell-Based Immunotherapy
Novel Non-Convalent Thrombin Inhibitors
Novel Peptides as NS3-Serine Protease Inhibitors of Hepatitis C Virus
Novel Peptides as NS3-Serine Protease Inhibitors of Hepatitis C Virus
Selective Apoptosis of Neoplastic Cells by an Hla-Dr Specific Monoclonal Antibody
Novel Peptides as NS3-Serine Protease Inhibitors of Hepatitis C Virus
Inhibitors of Serine Protease Activity of Matriptase or MTSP1
Nucleic Acid Molecules Encoding a Transmembrane Serine Protease 7, the Encoded Polypeptides and Methods Based Thereon
Nucleic Acid Molecules Encoding Serine Protease CVSP14, the Encoded Polypeptides and Methods Based Thereon
Nucleic Acid Molecules Encoding a Transmembrane Serine Protease 9, the Encoded Polypeptides and Methods Based Thereon
Method for Determining Potency of Antigenic Presenting Cell Based Vaccines
Nucleic Acid Molecules Encoding a Transmembrane Serine Protease 10, the Encoded Polypeptides and Methods Based Thereon
Aromatic Heterocyclic Non-Covalent Inhibitors of Urokinase and Blood Vessel Formation
Method of Treatment of Hemorrhagic Disease Using a Factor Viia/Tissue Factor Inhibitor
Matriptase Inhibitors and Methods of Use
Composition and Method for Producing an Immune Response Against Tumor-Related Antigens
Hla-Dr Specific Antibodies, Compositions and Methods
Novel Peptides as NS3-Serine Protease Inhibitors of Hepatitis C Virus
Compositions and Methods for Dendritic Cell-Based Immunotherapy
Binding Proteins Specific for Human Matriptase
Process for Manufacture of Nematode-Extracted Anticoagulant Protein (Nap)
Compositions and Methods for Enhancement of Major Histocompatibility Complex Class I Restricted Antigen Presentation
Method of Treatment of Hemorrhagic Disease Using a Factor Viia/Tissue Factor Inhibitor
Small-Molecule Modulators of Trp-P8 Activity
Novel Peptides as NS3-Serine Protease Inhibitors of Hepatitis C Virus
Promiscuous Her-2/Neu CD4 T Cell Epitopes
Promiscuous Pap CD4 T Cell Epitopes
Small-Molecule Modulators of Trp-P8 Activity
Methods for Inducing a Natural Killer (Nk) Cell-Mediated Immune Response and for Increasing Nk Cell Activity
Nucleic Acid Molecules Encoding Transmembrane Serine Proteases, the Encoded Proteins and Methods Based Thereon
Small-Molecule Modulators of Trp-P8 Activity
Small-Molecule Modulators of Trp-P8 Activity
Peptides as NS3-Serine Protease Inhibitors of Hepatitis C Virus
Patent:
43,298 →
Application:
13/068,159 →
Promiscuous Her-2/Neu CD4 T Cell Epitopes
Methods for Inducing a Natural Killer (Nk) Cell-Mediated Immune Response and for Increasing Nk Cell Activity
Promiscuous Her-2/Neu CD4 T Cell Epitopes
Promiscuous Pap CD4 T Cell Epitopes
Gene Expression Markers for Predicting Overall Survival in Subjects Treated with Sipuleucel-T
Application:
15/268,267 →
Publication:
US 2017/0107580
Related Assignments
(9)
Other recorded transfers of the patents in this record — the chain of ownership.
Change of Name
Aug 30, 2012
From: SCHERING CORPORATION
To: MERCK SHARP & DOHME CORP.
Reel/Frame 028884/0151 →
Release of Security Interest
Feb 18, 2015
From: GE BUSINESS CAPITAL CORPORATION FORMERLY TRANSAMERICA BUSINESS CAPITAL CORPORATION
To: DENDREON CORPORATION
Reel/Frame 035034/0539 →
Assignment of Assignor's Interest
Jul 16, 2015
From: DENDREON CORPORATION, AND ITS WHOLLY OWNED SUBSIDIARIES, DENDREON HOLDINGS, LLC, DENDREON DISTRIBUTION, LLC, AND DENDREON MANUFACTORING, LLC
To: DRONE ACQUISITION SUB INC.
Reel/Frame 036126/0259 →
Change of Name
Jul 20, 2015
From: DRONE ACQUISITION SUB INC.
To: DENDREON PHARMACEUTICALS, INC.
Reel/Frame 036136/0181 →
Court Order
Jul 22, 2015
From: TRANSAMERICA BUSINESS CREDIT CORPORATION
To: DENDREON CORPORATION
Reel/Frame 036159/0256 →
Security Agreement
Jul 27, 2015
From: DENDREON PHARMACEUTICALS, INC.
To: BARCLAYS BANK PLC, AS COLLATERAL AGENT
Reel/Frame 036190/0503 →
Release of Security Interest
Jul 5, 2017
From: BARCLAYS BANK PLC
To: DENDREON PHARMACEUTICALS LLC
Reel/Frame 043089/0288 →
Corrective Assignment to Correct the Assignee Address Previously Recorded at Reel: 042389 Frame: 505. Assignor(S) Hereby Confirms the Change of Name.
Feb 14, 2018
From: DENDREON PHARMACEUTICALS, INC.
To: DENDREON PHARMACEUTICALS LLC
Reel/Frame 046088/0882 →
Merger
Aug 8, 2022
From: MERCK SHARP & DOHME CORP.
To: MERCK SHARP & DOHME LLC
Reel/Frame 061102/0145 →